Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Malignant Pleural Mesothelioma
NCT04996017Phase 3Recruiting
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Dec 2021
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in malignant pleural mesothelioma (MPM), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Dec 2021; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04996017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996017.